<DOC>
	<DOCNO>NCT02068131</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety recombinant anti-tumor anti-virus protein injection plus capecitabine treating patient metastatic colorectal cancer progress standard therapy .</brief_summary>
	<brief_title>Recombinant Anti-tumor Anti-virus Protein Injection Plus Xeloda Treatment Metastatic Colorectal Cancer</brief_title>
	<detailed_description>This Phase Ⅱ exploratory clinical study . The purpose study evaluate efficacy safety recombinant anti-tumor anti-virus protein injection plus capecitabine treating patient metastatic colorectal cancer progress standard therapy . All patient receive recombinant anti-tumor anti-virus protein injection capecitabine .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<criteria>Aged 18 year . Pathologically confirm metastatic adenocarcinoma colon rectum . All histological type exclude . Failure SecondLine secondline treatment , fluoropyrimidine irinotecan oxaliplatincontaining regimen . ( Subjects progress within 3 month follow last administration approve standard therapy terminate standard treatment due unacceptable toxicity warrant . ) .If recurrence metastasis occur within 6 month discontinuation adjuvant chemotherapy , adjuvant chemotherapy consider firstline treatment.Subject receive lastline treatment include capecitabine . At least one measurable lesion accord RECIST criterion previously local treat . Minimum indicator lesion size follow : great equal 10 mm measure spiral CT NMR.Malignant lymph node short diameter follow : great equal 15 mm measure spiral CT. ECOG performance status 0 , 1 2 . Minimum 4 week since local radiotherapy surgery control symptom severe complication ( local radiotherapy control bone metastases limit ) ，and adequately recovered toxicity prior therapy ) . Life expectancy least 3 month . Prior treatment novaferon . Pregnancy breastfeed woman woman may pregnant positive drug test administration . Patient childbearing potential ( male less 1 year postmenopausal woman ) reluctant take contraceptive measure . Patient allergic Interferonα interferonα antibody . Patients uncontrolled central nervous system ( CNS ) metastases .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>Metastatic Colorectal Cancer</keyword>
	<keyword>Novaferon</keyword>
	<keyword>Recombinant anti-tumor anti-virus protein injection</keyword>
	<keyword>xeloda</keyword>
</DOC>